Role of Sex Steroids in β Cell Function, Growth, and Survival

Trends in Endocrinology and Metabolism

Volumn 27, Issue 12, 2016, Pages 844-855

  Mauvais Jarvis, Franck ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

androgen; estrogen; insulin; islet; progesterone; cells

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIOL; ANDROSTENEDIONE; AROMATASE; CHOLESTEROL; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; NEUROSTEROID; PRASTERONE; PREGNENOLONE; PROGESTERONE; SEX HORMONE; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE;

CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CELL REGENERATION; CELL SURVIVAL; ENDOCRINE FUNCTION; ENERGY METABOLISM; GLUCOSE INTOLERANCE; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PUBERTY; REPRODUCTION; REVIEW; SEX DIFFERENCE; SEX DIFFERENTIATION; STEROIDOGENESIS; TESTIS FUNCTION; TESTOSTERONE SYNTHESIS; ANIMAL; METABOLISM;

ANDROGENS; ANIMALS; ESTROGENS; GONADAL STEROID HORMONES; HUMANS; INSULIN; INSULIN-SECRETING CELLS; PROGESTERONE;

EID: 84994715869     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.08.008     Document Type: Review

References (87)

1. 1 Halaas, J.L., et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269 (1995), 543–546.
2. 2 Drucker, D.J., The biology of incretin hormones. Cell Metab. 3 (2006), 153–165.
3. 3 Lee, N.K., et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130 (2007), 456–469.
4. 4 Song, W.J., et al. Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab. 19 (2014), 667–681.
5. 5 El Ouaamari, A., et al. SerpinB1 promotes pancreatic beta cell proliferation. Cell Metab. 23 (2016), 194–205.
6. 6 Bostrom, P., et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481 (2012), 463–468.
7. 7 Mauvais-Jarvis, F., et al. The role of estrogens in control of energy balance and glucose homeostasis. Endocr. Rev. 34 (2013), 309–338.
8. 8 Navarro, G., et al. The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity (Silver Spring) 23 (2015), 713–719.
9. 9 Miller, W.L., Auchus, R.J., The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32 (2011), 81–151.
10. 10 Baulieu, E.E., Robel, P., Neurosteroids: a new brain function?. J. Steroid Biochem. Mol. Biol. 37 (1990), 395–403.
11. 11 Morales, A., et al. Synthesis of steroids in pancreas: evidence of cytochrome P-450scc activity. Pancreas 19 (1999), 39–44.
12. 12 Martel, C., et al. Distribution of 17β-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J. Steroid Biochem. Mol. Biol. 41 (1992), 597–603.
13. 13 Mendoza-Hernandez, G., et al. 17β-Hydroxysteroid dehydrogenase activity in canine pancreas. Biochem. Biophys. Res. Commun. 152 (1988), 376–382.
14. 14 Miettinen, M.M., et al. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem. J. 314 (1996), 839–845.
15. 15 Sakurai, N., et al. Systemic distribution and tissue localizations of human 17β-hydroxysteroid dehydrogenase type 12. J. Steroid Biochem Mol. Biol. 99 (2006), 174–181.
16. 17α in beta-cells of rat pancreas and its local steroidogenesis. J. Steroid Biochem. Mol. Biol. 111 (2008), 80–86.
17. 17 Mendoza-Hernandez, G., et al. Δ5-3β-Hydroxysteroid dehydrogenase–isomerase activity in canine pancreas. Life Sci. 47 (1990), 467–475.
18. 18 Iqbal, M.J., et al. Sex-steroid enzymes, aromatase and 5α-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. Clin. Sci. (Lond.) 65 (1983), 71–75.
19. 19 Labrie, F., All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. J. Steroid Biochem. Mol. Biol. 145 (2015), 133–138.
20. 20 Tiano, J.P., Mauvais-Jarvis, F., Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes. Nat. Rev. Endocrinol. 8 (2012), 342–351.
21. 21 Beeson, P.B., Age and sex associations of 40 autoimmune diseases. Am. J. Med. 96 (1994), 457–462.
22. 22 Gale, E.A., Gillespie, K.M., Diabetes and gender. Diabetologia 44 (2001), 3–15.
23. 23 Blohme, G., et al. Male predominance of type 1 (insulin-dependent) diabetes mellitus in young adults: results from a 5-year prospective nationwide study of the 15-34-year age group in Sweden. Diabetologia 35 (1992), 56–62.
24. 24 Nystrom, L., et al. Risk of developing insulin-dependent diabetes mellitus (IDDM) before 35 years of age: indications of climatological determinants for age at onset. Int. J. Epidemiol. 21 (1992), 352–358.
25. 25 Weets, I., et al. Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes. Diabetologia 49 (2006), 1158–1162.
26. 26 Samuelsson, U., et al. Residual beta cell function at diagnosis of type 1 diabetes in children and adolescents varies with gender and season. Diabetes Metab. Res. Rev. 29 (2013), 85–89.
27. 27 Herold, K.C., et al. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat. Rev. Immunol. 13 (2013), 243–256.
28. 28 Christianson, M.S., et al. Multiple sclerosis at menopause: potential neuroprotective effects of estrogen. Maturitas 80 (2015), 133–139.
29. 29 Lateef, A., Petri, M., Hormone replacement and contraceptive therapy in autoimmune diseases. J. Autoimmun. 38 (2012), J170–J176.
30. 30 Islander, U., et al. Estrogens in rheumatoid arthritis; the immune system and bone. Mol. Cell. Endocrinol. 335 (2011), 14–29.
31. 31 Gourdy, P., et al. Estrogen therapy delays autoimmune diabetes and promotes the protective efficiency of natural killer T-cell activation in female nonobese diabetic mice. Endocrinology 157 (2016), 258–267.
32. 32 Shapiro, A.M., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343 (2000), 230–238.
33. 33 Hering, B.J., et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 293 (2005), 830–835.
34. 34 Shapiro, A.M., et al. International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 355 (2006), 1318–1330.
35. 35 Johnston, P.C., et al. Factors associated with islet yield and insulin independence after total pancreatectomy and islet cell autotransplantation in patients with chronic pancreatitis utilizing off-site islet isolation: Cleveland Clinic experience. J. Clin. Endocrinol. Metab. 100 (2015), 1765–1770.
36. 36 Liu, S., et al. Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. Diabetologia 56 (2013), 370–381.
37. 37 Hwang, H.J., et al. Improved islet transplantation outcome by the co-delivery of siRNAs for iNOS and 17β-estradiol using an R3V6 peptide carrier. Biomaterials 38 (2015), 36–42.
38. 38 Finan, B., et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat. Med. 18 (2012), 1847–1856.
39. 39 Schwenk, R.W., et al. GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 58 (2015), 604–614.
40. 40 Tiano, J.P., et al. Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis. Sci. Rep., 5, 2015, 10211.
41. 41 Tiano, J., et al. A glucagon-like peptide-1–estrogen fusion peptide shows enhanced efficacy in preventing insulin-deficient diabetes in mice. Endocr. Rev. 33 (2012), OR21–OR26.
42. 42 Komm, B.S., A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod. Sci. 15 (2008), 984–992.
43. 43 Kim, J.H., et al. Tissue-selective estrogen complexes with bazedoxifene prevent metabolic dysfunction in female mice. Mol. Metab. 3 (2014), 177–190.
44. 44 Kim, J., Mauvais-Jarvis, F., The combination of conjugated equine estrogens with bazedoxifene prevents streptozotocin-induced diabetes in female mice. Matters, 2016, 10.19185/matters.201605000017 Published online June 6, 2016.
45. 45 Le May, C., et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc. Natl. Acad. Sci. U.S.A. 103 (2006), 9232–9237.
46. 46 Xu, B., et al. Estrogen complexes improve the unfolded protein response and prevent ER-stress induced beta cell failure in Akita mice. Diabetes, 64, 2015, A35.
47. 47 Jacovetti, C., et al. MicroRNAs contribute to compensatory beta cell expansion during pregnancy and obesity. J. Clin. Invest. 122 (2012), 3541–3551.
48. 48 Van de Casteele, M., et al. Partial duct ligation: beta-cell proliferation and beyond. Diabetes 63 (2014), 2567–2577.
49. 49 Yuchi, Y., et al. Estrogen receptor alpha regulates beta-cell formation during pancreas development and following injury. Diabetes 64 (2015), 3218–3228.
50. 50 Inada, A., et al. Beta-cell induction in vivo in severely diabetic male mice by changing the circulating levels and pattern of the ratios of estradiol to androgens. Endocrinology 155 (2014), 3829–3842.
51. 51 Bernal-Mizrachi, E., et al. Human beta-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes 63 (2014), 819–831.
52. 52 Alonso-Magdalena, P., et al. Antidiabetic actions of an estrogen receptor beta selective agonist. Diabetes 62 (2013), 2015–2025.
53. 53 Chang, C.S., et al. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240 (1988), 324–326.
54. 54 Lubahn, D.B., et al. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240 (1988), 327–330.
55. 55 Tilley, W.D., et al. Characterization and expression of a cDNA encoding the human androgen receptor. Proc. Natl. Acad. Sci. U.S.A. 86 (1989), 327–331.
56. 56 Mauvais-Jarvis, F., Androgen-deprivation therapy and pancreatic beta-cell dysfunction in men. J. Diabetes Complications 30 (2016), 389–390.
57. 57 Navarro, G., et al. Extranuclear actions of the androgen receptor enhance glucose-stimulated insulin secretion in the male. Cell Metab. 23 (2016), 837–851.
58. 58 Smith, E.P., et al. The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 19 (2014), 1050–1057.
59. 59 Mauvais-Jarvis, F., Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol. Metab. 22 (2011), 24–33.
60. 60 O'Meara, N.M., et al. Defects in beta-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 76 (1993), 1241–1247.
61. 61 Dunaif, A., Finegood, D.T., Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81 (1996), 942–947.
62. 62 Holte, J., et al. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J. Clin. Endocrinol. Metab. 78 (1994), 1052–1058.
63. 63 Goodarzi, M.O., et al. β-Cell function: a key pathological determinant in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90 (2005), 310–315.
64. 64 Morford, J., et al. Excess androgen receptor activation produces hyperinsulinemia, insulin resistance, and secondary beta-cell failure in female mice. Diabetes 65:Suppl. 1 (2016), A458–A523.
65. 65 Veras, K., et al. DHEA supplementation in ovariectomized rats reduces impaired glucose-stimulated insulin secretion induced by a high-fat diet. FEBS Open Bio 4 (2014), 141–146.
66. 66 Roland, A.V., et al. Prenatal androgen exposure programs metabolic dysfunction in female mice. J. Endocrinol. 207 (2010), 213–223.
67. 67 Hogg, K., et al. The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep. PLoS ONE, 6, 2011, e24877.
68. 68 Rae, M., et al. The pancreas is altered by in utero androgen exposure: implications for clinical conditions such as polycystic ovary syndrome (PCOS). PLoS ONE, 8, 2013, e56263.
69. 69 Abbott, D.H., et al. Experimentally induced gestational androgen excess disrupts glucoregulation in rhesus monkey dams and their female offspring. Am. J. Physiol. Endocrinol. Metab. 299 (2010), E741–E751.
70. 70 Nicol, L.E., et al. Abnormal infant islet morphology precedes insulin resistance in PCOS-like monkeys. PLoS ONE, 9, 2014, e106527.
71. 71 Kalkhoff, R.K., et al. Progesterone, pregnancy and the augmented plasma insulin response. J. Clin. Endocrinol. Metab. 31 (1970), 24–28.
72. 72 Doglioni, C., et al. Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas. Am. J. Pathol. 137 (1990), 999–1005.
73. 73 Winborn, W.B., et al. Localization of progestin receptors in the islets of Langerhans. Pancreas 2 (1987), 289–294.
74. 74 Costrini, N.V., Kalkhoff, R.K., Relative effects of pregnancy, estradiol, and progesterone on plasma insulin and pancreatic islet insulin secretion. J. Clin. Invest. 50 (1971), 992–999.
75. 75 Nielsen, J.H., Direct effect of gonadal and contraceptive steroids on insulin release from mouse pancreatic islets in organ culture. Acta Endocrinol. (Copenh.) 105 (1984), 245–250.
76. 76 Shao, J., et al. Prolactin, progesterone, and dexamethasone coordinately and adversely regulate glucokinase and cAMP/PDE cascades in MIN6 beta-cells. Am. J. Physiol. Endocrinol. Metab. 286 (2004), E304–E310.
77. 77 Dong, F., et al. TCF7L2 involvement in estradiol- and progesterone-modulated islet and hepatic glucose homeostasis. Sci. Rep., 6, 2016, 24859.
78. 78 Nieuwenhuizen, A.G., et al. Proliferation of pancreatic islet-cells in cyclic and pregnant rats after treatment with progesterone. Horm. Metab. Res. 30 (1998), 649–655.
79. 79 Sorenson, R.L., et al. Effects of steroid and lactogenic hormones on islets of Langerhans: a new hypothesis for the role of pregnancy steroids in the adaptation of islets to pregnancy. Endocrinology 133 (1993), 2227–2234.
80. 80 Nieuwenhuizen, A.G., et al. Progesterone stimulates pancreatic cell proliferation in vivo. Eur. J. Endocrinol. 140 (1999), 256–263.
81. 81 Sutter-Dub, M.T., Effects of pregnancy and progesterone and/or oestradiol on the insulin secretion and pancreatic insulin content in the perfused rat pancreas. Diabete Metab. 5 (1979), 47–56.
82. 82 Picard, F., et al. Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta-cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 15644–15648.
83. 83 Zhang, M., et al. Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic beta cells. Mol. Cell. Proteomics 13 (2014), 3049–3062.
84. 84 Ahmed, I.S., et al. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J. Biol. Chem. 285 (2010), 24775–24782.
85. 85 Buteau, J., et al. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52 (2003), 124–132.
86. 86 Lee, H.Y., et al. Epidermal growth factor increases insulin secretion and lowers blood glucose in diabetic mice. J. Cell. Mol. Med. 12 (2008), 1593–1604.
87. 87 Nunes, V.A., et al. Progesterone induces apoptosis of insulin-secreting cells: insights into the molecular mechanism. J. Endocrinol. 221 (2014), 273–284.